Search Results for: CLINICAL TRIALS Accelerating the Clinical
Articles
Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma & Fluidda September 22, 2022
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products, recently announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging…..
SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
COMPASS Pathways Presents Largest Ever Study of Psilocybin Therapy May 23, 2022
COMPASS Pathways plc recently presented positive data from the largest randomized, controlled, double-blind study of psilocybin therapy ever completed, at...SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D January 13, 2022
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development...ARTIFICIAL INTELLIGENCE - Attempting to Speed Up Vaccine Development to Combat the Next Pandemic October 4, 2021
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
DRUG DEVELOPMENT - Simplifying the Drug Development Journey October 4, 2021
Fran DeGrazio explains how experienced and focused collaborators can provide guidance, support services, manpower, and intellect to make it easier to achieve all the goals needed in delivering a drug to a patient.
Genetron Health & IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline September 28, 2021
Genetron Holdings Limited recently announced a partnership with IMPACT Therapeutics in which the two parties will cooperate together on research and development for synthetic lethal inhibitors that are based on….
SPECIAL FEATURE - Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021
Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.
2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery June 29, 2021
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
WEARABLE PLATFORM - Next-Generation Wearable Drug Delivery: Prefilled Devices Provide a Truly Patient-Centric Solution June 2, 2021
Mindy Katz says with increasingly positive expectations for the wearable device market to provide an intuitive and user-friendly drug delivery experience, her company continues to optimize its wearable platform solution, investigating new technologies and processes to improve the offerings for patients and providers.
DRUG DEVELOPMENT EXECUTIVE - Quotient Sciences: Breaking Down the Silos Between Drug Substance & Drug Product June 1, 2021
Mark Egerton, PhD, CEO of Quotient Sciences, discusses how integrating these capabilities cuts through functional silos, simplifies drug development, and affirms Quotient’s belief that molecules need to become cures, fast.
Calithera Biosciences & Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708 May 19, 2021
Calithera Biosciences, Inc. and Antengene Corporation, Ltd. recently announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera’s small….
EXECUTIVE INTERVIEW - Pharmaceutics International, Inc: Getting Back to its Roots March 1, 2021
Sridhar Krishnan, Pii’s Senior Vice President, Operations and Strategic Initiatives, discusses how manufacturing is not solely where Pii wanted to be, so the company made a concerted effort to get back to its CDMO roots.
EXECUTIVE INTERVIEW - Pace Analytical® Life Sciences: Delivering Science Better; Advancing Novel Therapies Through the Clinic to Commercialization March 1, 2021
Frank Tagliaferri, PhD, Vice President of Pharmaceutical Development at PLS, discusses his experiences with the company and its recent growth.
Axovant Gene Therapies Announces FDA Clearance of IND for Gene Therapy November 11, 2020
Axovant Gene Therapies Ltd. recently announced the US FDA has lifted its clinical hold and cleared the Investigational New Drug (IND) Application to initiate a registrational study of….
MilliporeSigma’s New Platform Speeds Development of Cell & Gene Therapies October 14, 2020
MilliporeSigma has recently bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress Lentiviral Production Platform…..
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 September 9, 2020
RedHill Biopharma Ltd. recently announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral...Editas Medicine Enters Into Strategic Partnership With Catalent to Support Gene-Editing Medicine Pipeline July 29, 2020
Editas Medicine, Inc. and Catalent recently announced they have entered into a strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of….
WHITEPAPER: Lonza Engine® & Xcelodose®: Accelerating Preclinical & Clinical Trial Pathways With Target Dosing Technologies
Learn how Lonza helps developers quickly assess new drug candidates while minimizing API consumption through efficient excipient screenings, encapsulation and...
